Drug intelligence / Profile preview

toripalimab + uliledlimab

Development stage: Unknown
Lead developer: I-MAB
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This combination involves **toripalimab**, a PD-1 antibody, and **uliledlimab**, a CD73 antibody. Toripalimab works by blocking the PD-1/PD-L1 interaction, enhancing the body's immune response against cancer cells. Uliledlimab targets CD73, an enzyme involved in adenosine production, which can suppress immune responses in the tumor microenvironment. By inhibiting CD73, uliledlimab aims to enhance anti-tumor immunity. The combination is being studied for its efficacy and safety in treating advanced non-small cell lung cancer (NSCLC).

Brand names: TUOYI

Targets

PDCD1 (Programmed cell death protein 1 receptor)NT5E (Cluster of Differentiation 73)

Beyond the preview

Go deeper on toripalimab + uliledlimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on toripalimab + uliledlimab.

Explore the full profile